The thorough QT study – do we need more of the same?
Who gets antidotes? choosing the chosen few
Therapeutics in clinical toxicology: in the absence of strong evidence how do we choose between antidotes, supportive care and masterful inactivity
Treatment of drug-induced seizures
Pharmacological treatment of acquired QT prolongation and torsades de pointes
Flumazenil, naloxone and the ‘coma cocktail’
Antidotes to coumarins, isoniazid, methotrexate and thyroxine, toxins that work via metabolic processes
Adverse reactions to snake antivenom, and their prevention and treatment
Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies
Pharmacological treatment of organophosphorus insecticide poisoning: the old and the (possible) new
Evidence for the changing regimens of acetylcysteine
Activated charcoal for acute overdose: a reappraisal
Pharmacological treatment of cardiac glycoside poisoning
Treatment of sulfonylurea and insulin overdose
Antidotes for poisoning by alcohols that form toxic metabolites
Pharmacological management of anticholinergic delirium - theory, evidence and practice
Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability
Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach
Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy
Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing
A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC